February 07, 2019
Momenta Pharmaceuticals Inc. can't challenge a patent for Bristol-Myers Squibb Co.'s rheumatoid arthritis drug Orencia because Momenta has stopped developing a biosimilar version of the blockbuster product, the Federal Circuit ruled Thursday.
November 06, 2018
An infringement case over a Bristol-Myers Squibb Co. patent covering its Orencia biologics product is not moot simply because challenger Momenta Pharmaceuticals Inc. is considering stopping development of a proposed biosimilar, Momenta has told the Federal Circuit.
December 05, 2017
Pharmaceuticals company Bristol-Myers Squibb Co. asked the Federal Circuit Tuesday to reject for lack of standing a competitor's appeal of a U.S. Patent Trial and Appeal Board decision upholding its patent for a biologics product, saying the company cannot show injury because it has not yet developed a product that infringes the patent.